Ascentage Pharma Group International (NASDAQ:AAPG) Receives Buy Rating from BTIG Research

Ascentage Pharma Group International (NASDAQ:AAPG)‘s stock had its “buy” rating reiterated by research analysts at BTIG Research in a research report issued on Monday,Benzinga reports. They currently have a $48.00 price objective on the stock. BTIG Research’s target price would suggest a potential upside of 176.82% from the company’s previous close.

AAPG has been the subject of several other reports. B. Riley Financial began coverage on Ascentage Pharma Group International in a research report on Wednesday, June 10th. They set a “buy” rating and a $45.00 price objective for the company. Raymond James Financial restated a “buy” rating on shares of Ascentage Pharma Group International in a research report on Wednesday, June 10th. China Intl Cap upgraded Ascentage Pharma Group International to a “strong-buy” rating in a research report on Monday, April 6th. Finally, Deutsche Bank Aktiengesellschaft assumed coverage on Ascentage Pharma Group International in a research report on Friday, April 24th. They issued a “buy” rating and a $40.00 target price for the company. Two analysts have rated the stock with a Strong Buy rating and eight have issued a Buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Buy” and a consensus price target of $46.43.

Ascentage Pharma Group International Stock Down 1.5%

Shares of AAPG stock opened at $17.34 on Monday. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.77 and a current ratio of 1.79. Ascentage Pharma Group International has a twelve month low of $16.92 and a twelve month high of $48.45. The business has a fifty day simple moving average of $21.90 and a 200 day simple moving average of $24.59.

Ascentage Pharma Group International (NASDAQ:AAPG) last announced its quarterly earnings data on Wednesday, March 25th. The company reported ($0.52) earnings per share for the quarter. The company had revenue of $24.72 million during the quarter. On average, research analysts predict that Ascentage Pharma Group International will post -0.96 EPS for the current fiscal year.

Hedge Funds Weigh In On Ascentage Pharma Group International

A number of hedge funds have recently made changes to their positions in the stock. Citadel Advisors LLC bought a new position in shares of Ascentage Pharma Group International during the third quarter worth about $383,000. Hsbc Holdings PLC bought a new position in shares of Ascentage Pharma Group International during the second quarter worth about $391,000. UBS Group AG raised its position in shares of Ascentage Pharma Group International by 149.4% during the third quarter. UBS Group AG now owns 18,345 shares of the company’s stock worth $716,000 after acquiring an additional 10,988 shares during the last quarter. Finally, XY Capital Ltd raised its position in shares of Ascentage Pharma Group International by 224.2% during the third quarter. XY Capital Ltd now owns 18,120 shares of the company’s stock worth $707,000 after acquiring an additional 12,530 shares during the last quarter.

About Ascentage Pharma Group International

Ascentage Pharma Group International is a clinical?stage biopharmaceutical company focused on developing small?molecule therapeutics that modulate programmed cell death pathways, including the Bcl?2 family and the MDM2–p53 axis. Its pipeline features orally bioavailable inhibitors such as APG-2575, a selective Bcl-2 inhibitor, and APG-115, a potent MDM2 antagonist, both aimed at reactivating apoptosis in cancer cells across hematologic malignancies and solid tumors.

Founded in 2008 by biotechnology entrepreneur Dr.